Literature DB >> 10677696

Prevention of transfusional Trypanosoma cruzi infection in Latin America.

G A Schmunis1.   

Abstract

Trypanosoma cruzi is a protozoan infection widely spread in Latin America, from Mexico in the north to Argentina and Chile in the south. The second most important way of acquiring the infection is by blood transfusion. Even if most countries of Latin America have law/decree/norms, that make mandatory the screening of blood donors for infectious diseases, including T. cruzi (El Salvador and Nicaragua do not have laws on the subject), there is usually no enforcement or it is very lax. Analysis of published serologic surveys of T. cruzi antibodies in blood donors done in 1993, indicating the number of donors and screening coverage for T. cruzi in ten countries of Central and South America indicated that the probability of receiving a potentially infected transfusion unit in each country varied from 1,096 per 10,000 transfusions in Bolivia, the highest, to 13.02 or 13.86 per 10,000 transfusions in Honduras and Venezuela respectively, where screening coverage was 100%. On the other hand the probability of transmitting a T. cruzi infected unit was 219/10,000 in Bolivia, 24/10,000 in Colombia, 17/10,000 in El Salvador, and around 2-12/10,000 for the seven other countries. Infectivity risks defined as the likelihood of being infected when receiving an infected transfusion unit were assumed to be 20% for T. cruzi. Based on this, estimates of the absolute number of infections induced by transfusion indicated that they were 832, 236, and 875 in Bolivia, Chile and Colombia respectively. In all the other countries varied from seven in Honduras to 85 in El Salvador. Since 1993, the situation has improved. At that time only Honduras and Venezuela screened 100% of donors, while seven countries, Argentina, Colombia, El Salvador, Honduras, Paraguay, Uruguay and Venezuela, did the same in 1996. In Central America, without information from Guatemala, the screening of donors for T. cruzi prevented the transfusion of 1,481 infected units and the potential infection of 300 individuals in 1996. In the same year, in seven countries of South America, the screening prevented the transfusion of 36,017 infected units and 7, 201 potential cases of transfusional infection.

Entities:  

Mesh:

Year:  1999        PMID: 10677696     DOI: 10.1590/s0074-02761999000700010

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  17 in total

1.  A Critical Assessment of Officially Reported Chagas Disease Surveillance Data in Mexico.

Authors:  Ellen M Shelly; Rodolfo Acuna-Soto; Kacey C Ernst; Charles R Sterling; Heidi E Brown
Journal:  Public Health Rep       Date:  2016 Jan-Feb       Impact factor: 2.792

2.  Selective Testing of At-Risk Blood Donors for Trypanosoma cruzi and Plasmodium spp. in Switzerland.

Authors:  Christoph Niederhauser; Jochen Gottschalk; Caroline Tinguely
Journal:  Transfus Med Hemother       Date:  2016-05-03       Impact factor: 3.747

3.  Enzyme-linked immunosorbent assay for serological diagnosis of Chagas' disease employing a Trypanosoma cruzi recombinant antigen that consists of four different peptides.

Authors:  A W Ferreira; Z R Belem; E A Lemos; S G Reed; A Campos-Neto
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

4.  Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.

Authors:  Juan C Engel; Kenny K H Ang; Steven Chen; Michelle R Arkin; James H McKerrow; Patricia S Doyle
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

5.  Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV.

Authors:  Wesley C Van Voorhis; Lynn K Barrett; Richard T Eastman; Ryan Alfonso; Kent Dupuis
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

6.  Serodiagnosis of chronic and acute Chagas' disease with Trypanosoma cruzi recombinant proteins: results of a collaborative study in six Latin American countries.

Authors:  Eufrosina S Umezawa; Alejandro O Luquetti; Gabriela Levitus; Carlos Ponce; Elisa Ponce; Diana Henriquez; Susana Revollo; Bertha Espinoza; Octavio Sousa; Baldip Khan; José Franco da Silveira
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

7.  Risk factors associated with triatomines and its infection with Trypanosoma cruzi in rural communities from the southern region of the State of Mexico, Mexico.

Authors:  Imelda Medina-Torres; Juan C Vázquez-Chagoyán; Roger I Rodríguez-Vivas; Roberto Montes de Oca-Jiménez
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

8.  Changing Epidemiology and Approaches to Therapy for Chagas Disease.

Authors:  Louis V. Kirchhoff
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

9.  Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).

Authors:  Maite Vallejo; Pedro Pa Reyes; Mireya Martinez Garcia; Alejandro G Gonzalez Garay
Journal:  Cochrane Database Syst Rev       Date:  2020-12-11

10.  A model for Chagas disease with oral and congenital transmission.

Authors:  Daniel J Coffield; Anna Maria Spagnuolo; Meir Shillor; Ensela Mema; Bruce Pell; Amanda Pruzinsky; Alexandra Zetye
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.